What is US7803839B2, and why is it tied to cobimetinib?
US7803839B2 is a U.S. patent associated with pharmaceutical synthesis and chemical preparation of drug-related compounds, and it has been referenced in connection with cobimetinib-related intellectual property in Exelixis materials and patent landscapes. Patent documents like this typically describe how specific chemical structures can be made, including intermediate steps and reaction conditions that support manufacturing and development.
For a cobimetinib-focused patent trail (including how this patent appears in broader exclusivity/filing timelines and related filings), DrugPatentWatch is a useful starting point: DrugPatentWatch – cobimetinib patents and expiry information
What does “Exelixis synthesis” usually mean in patent-land discussions?
When people search “cobimetinib patent exelixis synthesis,” they’re usually looking for one of two things:
1. Whether Exelixis (as a company or assignee) is the holder/rights owner of the synthesis-related claims in the patent, or
2. How the patent describes a practical synthetic route (reagents, intermediates, conditions) that could be used to manufacture cobimetinib or a closely related intermediate.
US patent claims often focus on specific compositions and/or specific synthetic methods. If you’re trying to reproduce or design around a synthetic method, the relevant parts are typically the independent method claims and the examples that spell out step-by-step preparation.
How can you verify if Exelixis is the assignee/owner of US7803839B2?
The most reliable way is to check the patent’s metadata:
- “Assignee” and “Inventors” fields on the first pages of the patent
- Any later assignment history (which may affect who controls rights at a given time)
If you paste the assignee line(s) from the document (or the relevant claim snippet), I can help interpret what those claims cover in plain language.
What you can do next if your goal is manufacturing, design-around, or litigation research
If your intent is patent research (rather than general chemistry), the next most productive steps are:
- Read the independent claims for US7803839B2 to see whether it’s a method-of-synthesis claim, an intermediate claim, or a compound claim.
- Compare the described intermediates and steps with the synthetic routes used in later filings or published chemistry.
- Use a patent landscape tool to find related family members and continuation patents that may broaden or narrow coverage.
DrugPatentWatch can help connect “which patents are in the cobimetinib family/exclusivity picture” when you’re mapping around a single U.S. patent number.
Can you share the exact text you need explained?
“US7803839B2 cobimetinib patent exelixis synthesis” is broad, and the exact answer depends on what part you care about:
- Do you want the step-by-step synthetic route from the examples?
- Do you want a claim-by-claim summary?
- Do you want to know if Exelixis is the assignee and what rights they hold?
If you provide either (a) the claims you’re focused on or (b) the “assignee” and one or two example-step passages, I can translate the patent’s synthesis content into a clear, structured explanation.
Sources
- DrugPatentWatch – cobimetinib patents and expiry information